Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12141051 | 0.85 | CYP4F2 (0.46) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL12141071 | 0.84 | CYP4F2 (0.42) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL12141060 | 0.84 | CYP4F2 (0.42) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL5527738 | 0.81 | CYP4F2 (0.42) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL6876483 | 0.80 | CYP2C19 (0.48) | CYP2C19ALDH1A1 | |
| SCHEMBL8278858 | 0.80 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL3468351 | 0.79 | CYP4F2 (0.43) | CYP4F2CYP4A11NPSR1CYP2C19L3MBTL1 | |
| SCHEMBL15572899 | 0.78 | CYP4F2 (0.51) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL3725050 | 0.77 | CYP4F2 (0.47) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL3468020 | 0.76 | CYP4F2 (0.40) | CYP4F2CYP4A11NPSR1CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459525-B1 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF -AMINO- - HYDROXY AMIDES | MERCK SHARP & DOHME (US) | 2017-03-01 | — | — | EP | disclosed |
| US-8680294-B2 | Enantio- and stereo specific synthesis of β-amino-α-hydroxy amides | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680294-B2 | Enantio- and stereo specific synthesis of β-amino-α-hydroxy amides | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120178942-A1 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF BETA-AMINO-ALPHA- HYDROXY AMIDES | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178942-A1 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF BETA-AMINO-ALPHA- HYDROXY AMIDES | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2011014494-A1 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES | SCHERING CORPORATION (US) | 2011-02-03 | — | — | WO | disclosed |
| US-7399749-B2 | Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178942-A1 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF BETA-AMINO-ALPHA- HYDROXY AMIDES | CYP8B1, DAO, ASPH | CYP4F2 91/4885CYP4A11 85/4885NPSR1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.